."their serious adverse incident process has been wholly inadequate and what we have heard this week is a damning indictment of the western trust..: "arise: a phase 3 randomized trial of erenumab for episodic migraine.".
andrew kaye, head of policy at macmillan cancer support said it was �shocking� that a cancer patient had to wait 541 days for treatment..
.
.
.
.